Moderna (MRNA) Stock Explodes 58% on Melanoma Breakthrough That Could Reshape Cancer Treatment

TLDR

• Moderna stock jumped around 58% in premarket trading Wednesday after a Phase 3 trial success for its mRNA-based melanoma vaccine
• The INTerpath-001 trial showed intismeran autogene combined with Merck’s Keytruda outperformed Keytruda alone in preventing melanoma recurrence
• This is the first positive Phase 3 readout for both an individualized neoantigen therapy and an mRNA-based cancer treatment
• The companies plan to present data at a medical meeting and engage with regulators about filing for approval
• Merck (MRK) stock rose around 6% on the news; the two companies have nine ongoing Phase 2 and Phase 3 trials across multiple cancer types

Moderna stock was up around 58% in premarket trading Wednesday after the company and Merck announced their melanoma vaccine combination beat Keytruda alone in a Phase 3 clinical trial. This is the first time an mRNA-based cancer therapy has cleared a Phase 3 bar.

Moderna, Inc., MRNA

The trial, called INTerpath-001, enrolled around 1,100 patients with completely resected stage IIB-IV melanoma. It tested intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, paired with Merck’s blockbuster immunotherapy drug Keytruda.

… Continue reading the full article at the original source below.